Ann: OrthoATI Rotator Cuff Study Success With Cross-Over Patients, page-66

Another important development for stem cell investors generally and OCC. Whilst autologous stem cell treatments have been approved any way by the FDA, so it less appropriate to OCC, this news important for the wider industry:

https://www.prnewswire.com/news-releases/federal-judge-enters-judgment-in-favor-of-cell-surgical-network-ending-lawsuit-brought-by-the-fda-301616731.html

Basically, a federal judge in California issued a landmark decision siding with the California Stem Cell Treatment Center (CSCTC) in a lawsuit brought by the U.S. Food and Drug Administration, ruling the defendants surgical procedure that uses patients' stem cells to treat a range of medical conditions does not fall under the FDA's regulatory jurisdiction.

Just more news greasing the wheels of an easy ATI application to market in the US. Ultimately OCC could begin providing ATI in the US without formal approval, via Physicians, not dissimilar to the Special Access Scheme in Australia, where Physicians can prescribe if they feel it beneficial to patients' treatment.